Lyra Therapeutics (LYRA) EBIT (2019 - 2025)
Quarterly EBIT rose 37.61% to -$7.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$31.0 million through Dec 2025, up 67.8% year-over-year, with the annual reading at -$31.0 million for FY2025, 67.8% up from the prior year.
Lyra Therapeutics' EBIT history spans 7 years, with the latest figure at -$7.1 million for Q4 2025.
- EBIT came in at -$7.1 million for Q4 2025, down from -$6.2 million in the prior quarter.
- In the past five years, EBIT ranged from a high of -$6.2 million in Q3 2025 to a low of -$49.0 million in Q2 2024.
- The 5-year median for EBIT is -$13.0 million (2021), against an average of -$14.7 million.
- Year-over-year, EBIT tumbled 196.76% in 2024 and then surged 81.98% in 2025.
- Lyra Therapeutics' EBIT stood at -$13.6 million in 2021, then fell by 11.12% to -$15.2 million in 2022, then dropped by 8.72% to -$16.5 million in 2023, then surged by 30.76% to -$11.4 million in 2024, then skyrocketed by 37.61% to -$7.1 million in 2025.
- Per Business Quant, the three most recent readings for LYRA's EBIT are -$7.1 million (Q4 2025), -$6.2 million (Q3 2025), and -$8.8 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 642.90 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | -3.82 Mn |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Lyra Therapeutics | - | - | - | -7.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -7.12 Mn |
| Sep 30, 2025 | -6.24 Mn |
| Jun 30, 2025 | -8.83 Mn |
| Mar 31, 2025 | -8.84 Mn |
| Dec 31, 2024 | -11.41 Mn |
| Sep 30, 2024 | -12.44 Mn |
| Jun 30, 2024 | -48.97 Mn |
| Mar 31, 2024 | -23.52 Mn |
| Dec 31, 2023 | -16.48 Mn |
| Sep 30, 2023 | -16.83 Mn |
| Jun 30, 2023 | -16.50 Mn |
| Mar 31, 2023 | -17.31 Mn |
| Dec 31, 2022 | -15.16 Mn |
| Sep 30, 2022 | -14.83 Mn |
| Jun 30, 2022 | -14.40 Mn |
| Mar 31, 2022 | -11.93 Mn |
| Dec 31, 2021 | -13.64 Mn |
| Sep 30, 2021 | -11.08 Mn |
| Jun 30, 2021 | -11.07 Mn |
| Mar 31, 2021 | -7.83 Mn |
| Dec 31, 2020 | -7.05 Mn |
| Sep 30, 2020 | -6.36 Mn |
| Jun 30, 2020 | -4.55 Mn |
| Mar 31, 2020 | -4.25 Mn |
| Dec 31, 2019 | -4.39 Mn |
| Sep 30, 2019 | -4.23 Mn |
| Jun 30, 2019 | -4.28 Mn |
| Mar 31, 2019 | -3.62 Mn |